Seaweed Dietetic Food for the Functional Gastrointestinal Complaint Treatment


Despite the common nature of dyspeptic complaints, the treatment is still a problem. There is very little research done on the impact of dietary nutrition on the general health of the patients with dyspeptic complaints and overall nutritional safety. Study Objective: To evaluate the clinical effectiveness of the brown seaweed dietary product “Vitamarine” for the treatment of dyspepsia, as well as product safety. Material and Methods: An open, uncontrolled pilot study with questionnaires before and after the vitamarine course with the patient’s self-perception reports. Data were processed with multivariate analysis. Results: The study included 46 patients with 45 valid end result questionnaires for data processing. After 8 to 10 days use of vitamarine, 33 (76.8%) patients noted symptom disappearance or significant improvement, no improvement of symptoms or their increase was noted by 10 patients (23.2%). Complaints about weakness, fatigue and rapid tiredness significantly decreased or disappeared entirely (p = 0.04), including months long epi-gastric pain (p = 0.02) and constipation (p = 0.01). Conclusions: 1) Use of the dietetic food product “Vitamarine” with a dose of 50 - 60 g per day in two cases out of three improve the general well-being of the patients: months long dyspeptic abdominal pain and constipation disappear or significantly decrease. 2) In the first 8 - 10 days of the vitamarine course clinical effectiveness already can be noted. 3) Use of vitamarine is safe, including patients with a history of allergies to medications, elderly and patients with concomitant diseases.

Share and Cite:

J. Pokrotnieks, A. Derovs, E. Derova, D. Zandere, A. Odinets and V. Mishailov, "Seaweed Dietetic Food for the Functional Gastrointestinal Complaint Treatment," Food and Nutrition Sciences, Vol. 4 No. 9, 2013, pp. 893-907. doi: 10.4236/fns.2013.49117.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. A. N. Nyrop, O. S. Palsson, R. L. Levy, M. V. Korff, A. D. Feld, M. J. Turner and W. E. Whitehead, “Costs of Health Care for Irritable Bowel Syndrome, Chronic Con stipation, Functional Diarrhoea and Functional Abdomi nal Pain,” Alimentary Pharmacology & Therapeutics, Vol. 26, No. 2, 2007, pp. 237-248. doi:10.1111/j.1365-2036.2007.03370.x
[2] A. P. S. Hungin, C. Hill and A. Ragunath, “Systematic Review: Frequency and Reasons for Consultation for Gastro-Oesophageal Reflux Disease and Dyspepsia,” Ali mentary Pharmacology & Therapeutics, Vol. 30, No. 4, 2009, pp. 331-342. doi:10.1111/j.1365-2036.2009.04047.x
[3] 2009.
[4] 2009.
[5] N. B. Vakil, “Upper GI Disorders: New Directions in the Management of Dyspepsia and GERD. DDW2007,” 2009.
[6] E. M. M. Quigley and J. Keohane, “Dyspepsia,” Current Opinion in Gastroenterology, 2009.
[7] M. Pajala, M. Heikkinen and J. Hintikka, “A Prospective 1-Year Follow-Up Study in Patients with Functional or Organic Dyspepsia: Changes in Gastrointestinal Symp toms, Mental Distress and Fear of Serious Illness,” Ali mentary Pharmacology & Therapeutics, Vol. 24, No. 8, 2006, pp. 1241-1246. doi:10.1111/j.1365-2036.2006.03108.x
[8] M. Zvolinska-Wcislo and D. Galicka-Latala, “Epidemio logy, Classification and Management of Functional Dys pepsia,” Przeglad Lekarski, Vol. 65, No. 12, 2008, pp. 867-873.
[9] M. Corsetti, P. Caenepeel, B. Fischler, J. Janssens and J. Tack, “Impact of Coexisting Irritable Bowel Syndrome on Symptoms and Pathophysiological Mechanisms in Func tional Dyspepsia,” The American Journal of Gastroen terology, Vol. 99, No. 6, 2004, pp. 1152-1159.
[10] L. A. Van Kerkhoven, R. J. Laheij, V. Meineche-Schmidt, S. J. Veidhuyzen-Van Zatlen, N. J. de Wit and J. B. Jan sen, “Functional Dyspepsia: Not All Roads Seem to Lead to Rome,” Journal of Clinical Gastroenterology, Vol. 43, No. 2, 2009, pp. 118-122. doi:10.1097/MCG.0b013e31815591f7
[11] K. Monkemuller and P. Malfertheiner “Drug Treatment of Functional Dyspepsia,” World Journal of Gastroen terology, Vol. 12, No. 17, 2006, pp. 2594-2700.
[12] L. Agreus, N. J. Talley, A. Sheen, S. E. Johansson, M. P. Jones and K. Svardsudd, “Predictors and Non-Predictors of Symptom Relief in Dyspepsia Consultations in Pri mary Care,” Digital Distribution, Vol. 26, No. 3, 2008, pp. 248-255. doi:10.1159/000121355
[13] L. Van Oudenhove, J. Vandenberghe, B. Geeraerts, R. Vos, P. Persoons, B. Fischler, K. Demyttenaere and J. Tack, “Determinantsof Symptoms in Functional Dyspep sia: Gastric Sensomotor Function, Psychosocial Factors or Somatisation?” Gut, Vol. 57, No. 12, 2008, pp. 1666 1673.
[14] C. Feinle-Bisset and M. Horowitz, “Dietary Factors in Functional Dyspepsia,” Neurogastroenterology & Motil ity, Vol. 18, No. 8, 2006, pp. 608-618. doi:10.1111/j.1365-2982.2006.00790.x
[15] A. Madisch, G. Holtmann, G. Mayr, B. Vinson and J. Hotz, “Treatment of Functional Dyspepsia with a Herbal Preparation. A Double-Blind, Randomized, Placebo-Con trolled, Multicenter Trial,” Digestion, Vol. 69, No. 1, 2004, pp. 45-52. doi:10.1159/000076546
[16] J. Tack and S. Müller-Lissner, “Treatment of Chronic Constipation: Current Pharmacologic Approaches and Fu ture Directions,” Clinical Gastroenterology and Hepato logy, Vol. 7, No. 5, 2009, pp. 502-508. doi:10.1016/j.cgh.2008.12.006
[17] N. S. Abraham, P. Moayyedi, B. Daniels and S. J. O. Veldhuyzen Van Zanten, “The Methodological Quality of Trials Affects Estimates of Treatment Efficacy in Func tional (Non-Ulcer) Dyspepsia,” Alimentary Pharmacol ogy & Therapeutics, Vol. 19, No. 6, 2004, pp. 631-641. http://www.medscape.
[18] 2009. = 1&queryText = fatigue
[19] E. Fuller-Thomson and J. Nimigon, “Factors Associated with Depression among Individuals with Chronic Fatigue Syndrome: Findings from a Nationally Representative Survey,” Family Practice, Vol. 25, No. 6, 2008, pp. 414 422. doi:10.1093/fampra/cmn064
[20] C. H. Temml, “Epigastric Pain,” Wiener Medizinische Wochenschrift, Vol. 151, No. 9-10, 2001, pp. 219-223.
[21] D. Drossman, “The Launching of Rome III,” 2009. (
[22] 2009.
[23] G. Holtmann, “Reflux Disease: The Disorder of the Third Millennium,” European Journal of Gastroenterology & Hepatology, Vol. 13, No. Suppl 1, 2001, pp. S5-S11.
[24] D. A. Owen, “Gastritis and Carditis,” Modern Pathology, Vol. 16, No. 4, 2003, pp. 325-341. doi:10.1097/01.MP.0000062995.72390.14
[25] A. Agrawal and P. J. Whorwell, “Review Article: Abdo minal Bloating and Distension in Functional Gastrointes tinal Disorders—Epidemiology and Exploration of Possi ble Mechanisms,” Alimentary Pharmacology & Thera peutics, Vol. 27, No. 1, 2008, pp. 2-10. doi:10.1111/j.1365-2036.2007.03549.x
[26] B. D. Cash, E. Chang, N. J. Talley and A. Wald, “Fresh Perspectives in Chronic Constipation and Other Func tional Bowel Disorders,” Reviews in Gastroenterological Disorders, Vol. 7, No. 3, 2007, pp. 116-133.
[27] 2009.
[28] S. K. Papageorgiou, F. K. Katsaros, E. P. Kouvelos, J. W. Nolan, H. Le Deit and N. K. Kanellopoulos, “Haevy Metal Sorbtion by Calcium Alginate Beads from Lami naria digitata,” Journal of Hazardous Materials, Vol. 137, No. 3, 2006, pp. 1765-1772. doi:10.1016/j.jhazmat.2006.05.017
[29] A. V. Podkorytova, N. M. Aminina, M. M. Levachev and V. A. Miroshnichenko, “Functional Properties of Algi nates and Their Use in Therapeutic-Prophylactic Nutri tion,” Voprosy Pitaniia, No. 3, 199, pp. 26-29.
[30] S. K. Papageorgiou, F. K. Katsaros, E. P. Kouvelos, J. W. Nolan, H. Le Deit and N. K. Kanellopoulos, “Heavy Metal Sorption by Calcium Alginate Beads from Lami naria digitata,” Journal of Hazardous Materials, Vol. 137, No. 3, 2006, pp. 1765-1772. doi:10.1016/j.jhazmat.2006.05.017
[31] K. G. Mandel, B. P. Daggy, D. A. Brodie and H. I. Jaco by, “Review Article: Alginate-Raft Formulations in the Treatment of Heartburn and Acid Reflux,” Alimentary Pharmacology & Therapeutics, Vol. 14, No. 6, 2000, pp. 669-690. doi:10.1046/j.1365-2036.2000.00759.x
[32] K. H. Kim, Y. W. Kim, H. B. Kim, B. J. Lee and D. S. Lee, “Anti-Apoptotic Activity of Laminarin Polysaccha rides and Their Enzymatically Hydrolyzed Oligosaccha rides from Laminaria japonica,” Biotechnology Letters, Vol. 28, No. 6, 2006, pp. 239-246.
[33] J. Wang, Q. Zhang, Z. Zhang and Z. Li, “Antioxydant Activity of Sulfated Polysaccharide Fractions Extracted from Laminaria japonica,” International Journal of Bio logical Macromolecules, Vol. 42, No. 2, 2008, pp. 127-132. doi:10.1016/j.ijbiomac.2007.10.003
[34] P. J. Park, E. K. Kim, S. J. Lee, S. Y. Park, D. S. Kang, B. M. Jung, K. S. Kim, J. Y. Je and C. B. Ahn, “Protective Effects against H2O2-Induced Damage by Enzymatic Hy drolysates of an Edible Brown Seaweed, Sea Tangle (La minaria japonica),” Journal of Medicinal Food, Vol. 12, No. 1, 2009, pp. 159-166. doi:10.1089/jmf.2007.0675
[35] J. Wiese, V. Thiel, K. Nagel, T. Staufenberger and J. F. Imhoff, “Diversity of Antibiotic-Active Bacteria Associ ated with Brown Alga Laminaria saccharina from the Baltic Sea,” Marine Biotechnology (New York), Vol. 11, No. 2, 2009, pp. 287-300. doi:10.1007/s10126-008-9143-4
[36] A. Jonasson, “Laminaria—A Modern Cervix Dilatation Method with More than a 100-Year History,” Jordemo dern, Vol. 97, No. 6, 1984, pp. 187-195.
[37] A. M. Darwish, A. M. Ahmad and A. M. Mohammad, “Cervical Priming Prior Operative Hysteroscopy: A Ran domised Comparison of Laminaria versus Misoprostol,” Human Reproduction, Vol. 19, No. 10, 2004, pp. 2391-2394. doi:10.1093/humrep/deh397
[38] M. A. Burnett, C. A. Corbett and R. J. Gertenstein, “A Randomised Trial of Laminaria Tents versus Vaginal Misoprostol for Cervical Ripening in First Trimester Sur gical Abortion,” Journal of Obstetrics and Gynaecology Canada, Vol. 27, No. 1, 2005, pp. 38-42.
[39] 2009.
[40] N. Kawano, Y. Egashira and H. Sanada, “Effect of Die tary Fiber in Edible Seaweeds on the Development of D-Galactosamine-Induced Hepatopathy in Rats,” Journal of Nutritional Science and Vitaminology, Vol. 53, No. 5, 2007, pp. 446-450. doi:10.3177/jnsv.53.446
[41] D. Q. Jin, J. S. Kim, C. S. Yong, J. A. Kim and K. Huh, “Preventive Effects of Laminaria japonica Aqueous Ex tract on the Oxidative Activity in Streptozotocin-Induced Diabetic Rat Liver,” Biological and Pharmaceutical Bul letin, Vol. 27, No. 7, 2004, pp. 1037-1040. doi:10.1248/bpb.27.1037
[42] 2009.
[43] E. V. Rudichenko, T. A. Gvozdenko and M. V. Antoniuk, “Impact of Dietotherapy with Enterosorbent of Marine Origin on the Indices of Mineral and Lipid Metabolism for Patients Suffering from Kidney Diseases,” Voprosy Pitaniia, Vol. 74, No. 4, 2005, pp. 33-35.
[44] M. Bonneville, P. Saint-Mezard, J. Etiere, A. Hennino, I. Pernet, A. Denis and J. F. Nicolas, “Laminaria Ochro leuca Extract Reduces Skin Inflammation,” Journal of the European Academy of Dermatology and Venereology, Vol. 21, No. 8, 2007, pp. 1124-1125. doi:10.1111/j.1468-3083.2006.02111.x
[45] M. E. Lazovskaja, “Effectiviness of Using the Biologi cally Active Additive to Food from Laminaria in Adole scents during Complex Treatment of the Pulmonary Tu berculosis,” Voprosy Pitaniia, Vol. 74, No. 1, 2005, pp. 40-43.
[46] F. Rodriques-Adrados, “Rapid Dilatation of Esophageal and Laryngo-Tracheal Strictures by Laminaria Tents,” Revue de Laryngologie-Otologie-Rhinologie, Vol. 96, No. 9-10, 1975, pp. 1529-1534.
[47] Q. Zhang and J. Song, “Toxicological Evaluation of Fuc oidan Extracted from Laminaria japonica in Wistar Rats,” Food and Chemical Toxicology, Vol. 43, No. 3, 2005, pp. 421-426. doi:10.1016/j.fct.2004.12.001
[48] M. Chanda, P. Mackenzie and J. H. Day, “Hypersensiti vity Reactions Following Laminaria Placement,” Contra ception, Vol. 62, No. 2, 2000, pp. 105-106. doi:10.1016/S0010-7824(00)00145-1
[49] H. J. Jeong, S. A. Lee, P. D. Moon, H. J. Na, R. K. Park, J. Y. Um, H. M. Kim and S. H. Hong, “Alginic Acid Has Anti-Anaphylactic Effects and Inhibits Inflammatory Cy tokine Expression via Suppression of Nuclear Factor kappaB Activation,” Clinical & Experimental Allergy, Vol. 36, No. 6, 2006, pp. 785-794. doi:10.1111/j.1365-2222.2006.02508.x
[50] K. Miyai, T. Tokushige and M. Kondo, “Supression of Thyroid Function during Ingestion of Seaweed Kombu (Laminaria japonica) in Normal Japanese Adults,” Endo crine Journal, Vol. 55, No. 6, 2008, pp. 1103-1108. doi:10.1507/endocrj.K08E-125
[51] 2009.
[52] “Use of Homogenized Brown Seaweed Gel in Therapeu tic and Prophylactic Dietetic Nutrition,” Medical Tech nologies Brochure, Моscow, 2006.
[53] 2009.
[54] 2009.
[55] W. H. Wang, J. Q. Huang, G. F. Zheng, H. H. Xia, W. M. Wong, X. G. Liu, J. Karlberg and B. C.Wong, “Effects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-Analysis of Randomised Placebo-Controlled Tri als,” Clinical Gastroenterology and Hepatology, Vol. 5, No. 2, 2007, pp. 178-185. doi:10.1016/j.cgh.2006.09.012
[56] 2009.
[57] 2009.
[58] 2009.
[59] J. P. Uspenski, I. G. Pakhomova and V. N. Bubiakina, “Alginate-Containing Preparation Gaviscon for Patients with Gastroesophaginal Reflux Complicated with Chronic Pancreatitis: Pathogenetic Substantiation of Clinical Use Prospects,” Eksperimental’naia i Klinicheskaia Gastroen terologiia, No. 1, 2008, pp. 96-101.
[60] J. Hammer and N. J. Talley, “Disturbed Bowel Habits in Patients with Non-Ulcer Dyspepsia,” Alimentary Phar macology & Therapeutics, Vol. 24, No. 2, 2006, pp. 405-410.
[61] V. Meineche-Schmidt and T. Jorgensen, “‘Alarm Symp toms’ in Patients with Dyspepsia: A Three-Year Prospec tive Study from General Practice,” Scandinavian Journal of Gastroenterology, Vol. 37, No. 9, 2002, pp. 999-1007. doi:10.1080/003655202320378167
[62] M. P. Jones, N. J. Talley, G. D. Eslick, D. Dubois and J. Tack, “Community Subgroups in Dyspepsia and Their Association with Weight Loss,” The American Journal of Gastroenterology, Vol. 103, No. 8, 2008, pp. 2051-2060.
[63] K. M. Hoffmann, A. J. Eherer and G. J. Krejs, “Are Dys peptic Symptoms Linked to Helicobacter pylori? A Pro spective Cohort Study among Medical Students,” Wiener Klinische Wochenschrift, Vol. 115, No. 5-6, 2003, pp. 175-178. doi:10.1007/BF03040305
[64] G. Treiber, M. Schwabe, S. Ammon, S. Walker, U. Klotz and P. Malfertheiner, “Dyspeptic Symptoms Associated with Helicobacter pylori Infection Are Influenced by Strain and Host Specific Factors,” Alimentary Pharma cology & Therapeutics, Vol. 19, No. 2, 2004, pp. 219-231. doi:10.1111/j.1365-2036.2004.01751.x
[65] G. Piotrowicz, J. Milewski, B. Stepień and G. Rydzewska, “Characteristic and Endoscopic Evaluation of Dyspeptic Patients,” Polski Merkuriusz Lekarski, Vol. 22, No. 127, 2007, pp. 15-20.
[66] T. Tahara, T. Arisawa, T. Shibata, M. Nakamura, M. Okubo, D. Yoshioka, F. Wang, H. Nakano and I. Hirata, “Association of Endoscopic Appearances with Dyspeptic Symptoms,” Journal of Gastroenterology, Vol. 43, No. 3, 2008, pp. 208-215. doi:10.1007/s00535-007-2149-2
[67] E. Krustins, J. Derova, A. Pukitis and J. Pokrotnieks, “Patient Compliance in a Cohort of Patients in Latvia with Inflammatory Bowel Diseases,” St. Petersburg, 2009.
[68] H. Neumann, K. Monkemuller, A. Kandulski and P. Mal fertheiner, “Dyspepsia and IBS Symptoms in Patients with NERD, ERD and Barrett’s Esophagus,” Digestive Diseases, Vol. 26, No. 3, 2008, pp. 243-247. doi:10.1159/000121354
[69] T. O. Lipman, “The Role of Herbs and Probiotics in GI Wellness for Older Adults: Herbal Use for the GI Tract,” 2009.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.